Onychomycosis Clinical Trial
Official title:
An Evaluation of the Effect of the Erchonia LUNULA on Treating Toenail Onychomycosis
The purpose of this study is to determine whether low level laser light therapy is effective in the treatment of toenail onychomycosis.
An infection of toenail fungus, or onychomycosis, typically occurs when fungi (most commonly
dermatophytes) infect the nail, but may also be caused by yeasts and molds. The nail fungal
infection usually begins as a white or yellow spot under the tip of the toenail and then
spreads deeper into the nail causing discoloration, thickening and the development of
crumbling edges to the nail which can be unsightly and painful and may produce serious
physical and occupational limitations. Onychomycosis can also have a detrimental effect on
an individual's quality of life, affecting their psychosocial and emotional wellbeing.
Onychomycosis can be difficult to treat, and infections recur easily. Toenail fungus affects
approximately 23 million adults (about 10%) in the United States. It is more common among
older adults and tends to affect men more than women. Potential complications of
onychomycosis include pain, permanent damage to the nails and serious infections that can
spread beyond the feet.
Currently available treatments for onychomycosis include oral antifungal medications
(Lamisil, Sporanox); antifungal nail polish (Penlac); topical over-the-counter antifungal
creams; photodynamic therapy and in more severe cases, surgery to remove the nail. However,
there is no perfect cure for toenail fungus. Even the most effective oral medications are
only successful about half of the time, and topical medications are successful less than 10%
of the time. In addition, clearance of the infection and growth of new clear nail can be
slow, and the rate of recurrence of infection is high. Antifungal drugs may also cause side
effects ranging from skin rashes to liver damage.
Therefore, the need for a more effective and lasting cure is evident. Recently, research has
found laser therapy to show promise as a novel alternative treatment for toenail
onychomycosis. Unlike medication-driven treatments, laser therapy presents minimal risk of
side effects. Laser therapy is applied to toenail onychomycosis by shining a laser light
through the toenail. The laser light vaporizes the fungus while leaving the skin and
surrounding tissue unharmed.
Low level laser light therapy operates under the principle of photochemistry with a
photoacceptor molecule absorbing the emitted photons and inducing a biological cascade. Like
our eukaryotic cell, fungi contain the highly complex organelle the mitochondria, which is
responsible for the manufacturing of the energy molecule Adenosine triphosphate (ATP).
Within the inner mitochondrial membrane is cytochrome c oxidase, an identified photoacceptor
molecule. It is believed that laser therapy could perhaps provide a means to photo-destroy
the fungi responsible for onychomycosis by inducing the release of highly reactive
superoxides. Moreover, laser therapy has been shown to promote superoxide dismutase (SOD), a
process responsible for the destruction of foreign invaders. Extracellular release of low
levels of mediators associated with SOD can increase the expression of chemokines,
cytokines, and endothelial leukocyte adhesion molecules, amplifying the cascade that elicits
the inflammatory response. The physiologic function of hydrogen peroxide, superoxide anion,
and hydroxyl free radical is to destroy phagocytosed microbes. By enhancing the natural
processes of the immune system and impacting the structural integrity of the fungi strain,
it is believed that laser therapy may provide a means for clinicians to effectively treat
onychomycosis without the onset of any adverse events.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03098615 -
Study Evaluating the Effect of Jublia on Dermatophytomas
|
Phase 4 | |
Recruiting |
NCT01666002 -
Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
|
N/A | |
Completed |
NCT01180491 -
A Clinical Investigation on Early Visible Effects of Application of K101 During 8 Weeks on Discoloured and Deformed Nails Resulting From Onychomycosis
|
N/A | |
Terminated |
NCT01208168 -
Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails
|
Phase 3 | |
Terminated |
NCT01208129 -
Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails
|
Phase 3 | |
Completed |
NCT00385502 -
A Trial of the Safety and Efficacy of EcoNailâ„¢ in the Treatment of Fungus Infections of the Great Toenail
|
Phase 2 | |
Completed |
NCT00253305 -
Topical Gel Anti-Fungal Agent for Tinea Unguium
|
Phase 2 | |
Not yet recruiting |
NCT05809297 -
Diode Laser and Photodynamic Therapy Vs. Ciclopirox.
|
Phase 4 | |
Completed |
NCT03405818 -
An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents
|
Phase 4 | |
Completed |
NCT02588599 -
A Retrospective Analysis of the Effects of Low Level Laser Therapy on Toenail Onychomycosis
|
N/A | |
Recruiting |
NCT02436291 -
Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis
|
Phase 4 | |
Completed |
NCT01851590 -
Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis
|
Phase 4 | |
Completed |
NCT01452490 -
Diode Laser Treatment of Onychomycosis
|
N/A | |
Withdrawn |
NCT00938925 -
Effectiveness of Podiatry Care on Onychomycosis (EPOCAON)
|
N/A | |
Recruiting |
NCT00808366 -
Efficacy and Safety of RV4104A Ointment in Onychomycosis
|
N/A | |
Completed |
NCT00781820 -
Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste
|
Phase 3 | |
Completed |
NCT00768768 -
Iontophoretic Application of Terbinafine Gel to the Large Toe Nail
|
Phase 1 | |
Completed |
NCT00777868 -
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis
|
Phase 2 | |
Recruiting |
NCT06074315 -
Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis
|
N/A | |
Completed |
NCT01039883 -
A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule
|
Phase 1 |